|Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.|
|PMID: 18268279 Owner: NLM Status: MEDLINE|
|BACKGROUND: Prior thrombosis is a well-established risk factor for re-thrombosis in polycythemia vera and essential thrombocythemia but scarce data are available on the rate of re-thrombosis and the optimal strategy for prevention of recurrence. DESIGN AND METHODS: We retrospectively estimated the rate of recurrence in a multicenter cohort of 494 patients (poly-cythemia vera/essential thrombocythemia 235/259) with previous arterial (67.6%) or venous thrombosis (31%) or both (1.4%). First thrombosis was cerebrovascular disease in 191 cases, acute coronary syndrome in 106, peripheral arterial thrombosis in 44, and venous thromboembolism in 160. Microcirculatory events were not computed. RESULTS: Thrombosis recurred in 166 patients (33.6%), with an incidence of 7.6% patient-years. Sex, diagnosis (polycythemia vera or essential thrombocythemia), and presence of vascular risk factors did not predict recurrence, whereas age >60 years did (multivariable hazard ratio [HR], 1.67; 95% confidence interval [CI] 1.19-2.32). Increased leukocyte count at the time of the first thrombosis was a risk factor for recurrence in patients <60 years old (HR 3.55; 95% CI 1.02-12.25). Cytoreduction halved the risk in the overall cohort (HR 0.53; 95% CI 0.38-0.73) and the combination with antiplatelet agents or oral anticoagulants was more effective than administration of single drugs. Significant prevention of rethrombosis was independently achieved in patients with venous thromboembolism by both oral anticoagulants (HR 0.32; 95% CI 0.15-0.64) and antiplatelet agents (HR 0.42; 95% CI 0.22-0.77), in those with acute coronary syndrome by cytoreduction (HR 0.30; 95% CI 0.13-0.68), and in those with cerebrovascular disease by antiplatelet agents (HR 0.33; 95% CI 0.16-0.66). The overall incidence of major bleeding was 0.9% patient-years and rose to 2.8% in patients receiving both antiplatelet and anti-vitamin K agents. CONCLUSIONS: In patients with polycythemia vera and essential thrombocythemia, cytoreduction protects against recurrent thrombosis, particularly after acute coronary syndrome. The contemporary use of oral anticoagulants (after venous thromboembolism) or antiplatelet agents (after cerebrovascular disease or venous thromboembolism) further improves the protective effect. Such findings call for prospective studies aimed at investigating whether strategies tailored according to the type of first thrombosis could improve prevention of recurrences.|
|Valerio De Stefano; Tommaso Za; Elena Rossi; Alessandro M Vannucchi; Marco Ruggeri; Elena Elli; Caterina Micò; Alessia Tieghi; Rossella R Cacciola; Cristina Santoro; Giancarla Gerli; Nicola Vianelli; Paola Guglielmelli; Lisa Pieri; Francesca Scognamiglio; Francesco Rodeghiero; Enrico M Pogliani; Guido Finazzi; Luigi Gugliotta; Roberto Marchioli; Giuseppe Leone; Tiziano Barbui;|
Related Documents :
|22803489 - Prescribing trends for dabigatran etexilate in primary care.
22462729 - Levetiracetam may favorably affect seizure outcome after temporal lobectomy.
22669399 - Guided treatment improves outcome of patients with enterocutaneous fistulas.
22399509 - Recovery of the hypothalamic-pituitary-adrenal axis in children and adolescents after s...
20110009 - The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart di...
20886189 - Safety of thrombolysis in cerebral venous thrombosis. a systematic review of the litera...
17040339 - Topiramate prophylaxis and response to triptan treatment for acute migraine.
16804929 - Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiothe...
11081189 - Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resi...
|Type: Journal Article; Multicenter Study Date: 2008-02-11|
|Title: Haematologica Volume: 93 ISSN: 1592-8721 ISO Abbreviation: Haematologica Publication Date: 2008 Mar|
|Created Date: 2008-03-03 Completed Date: 2008-07-03 Revised Date: 2008-11-21|
Medline Journal Info:
|Nlm Unique ID: 0417435 Medline TA: Haematologica Country: Italy|
|Languages: eng Pagination: 372-80 Citation Subset: IM|
|Institute of Hematology, Catholic University, Largo Gemelli 8, 00168 Rome, Italy. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Acute Coronary Syndrome
Aged, 80 and over
Anticoagulants / adverse effects, therapeutic use
Arterial Occlusive Diseases / epidemiology, etiology
Hemorrhage / chemically induced
Platelet Aggregation Inhibitors / adverse effects, therapeutic use
Polycythemia Vera / blood, complications*, therapy
Stroke / epidemiology, etiology
Thrombocythemia, Essential / blood, complications*, therapy
Thrombophilia / etiology, genetics
Thrombosis / epidemiology, etiology*, prevention & control
Venous Thrombosis / epidemiology, etiology
|0/Anticoagulants; 0/Platelet Aggregation Inhibitors|
|Haematologica. 2008 Mar;93(3):331-5
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progen...
Next Document: A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-t...